Even more importantly, the existence of cancer-specific splicing variants of key genes, such as the AR or CCND1 in PCa, might offer a therapeutic opportunity for targeting proteins that are not expressed in healthy cells. Here, CCND1 is linked to posterior cortical atrophy.